Archive | Melanoma News

Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma

Fixed-dose nivolumab plus relatlimab-rmbw (Opdualag) elicited continued progression-free survival (PFS) benefit vs nivolumab (Opdivo) alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial (NCT03470922) that were presented at the 2022 ASCO Annual Meeting.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Iovance Biotherapeutics Releases Positive Clinical Data for Lifileucel in Advanced Melanoma

Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

New research confirms some melanomas may be harmless – but which ones?

Examine, a weekly newsletter covering the latest developments in science, is sent every Tuesday. Below is an excerpt – sign up to get the whole newsletter in your inbox.

Read the full story

Posted in Melanoma News, Patients, Latest News

Veterans at Higher Risk of Deadly Skin Cancers

TUESDAY, June 7, 2022 (HealthDay News) — U.S. veterans are at higher risk for melanoma, the deadliest form of skin cancer, than most Americans, and new research finds they are also more likely to have advanced-stage disease when it’s detected.

Read the full story

Posted in Melanoma News, Patients, Latest News